Latest news for isokin
Swiss-based pharmaceutical company Novartis () reported a 23 percent increase in fourth-quarter profit on Thursday. The company attributes much of the growth to the sales of its top two drugs Diovan and Glivec as well as successes in its generic drug unit. Audio Podcast: An audio podcast of this article is available at: Earnings were reported at $1. 66 billion in the forth quarter. This result was slightly lower than what analysts had forecast. On the Zurich market, Novartis shares dropped roughly 0. 5 percent. Overall sales for the company rose 16 percent in the last quarter of 2005. CEO Daniel Vasella said in a company statement, "The strong performance in 2006 stems from our commitment to innovation and reflects the impact of strengthening our healthcare portfolio. " Novartis said profits in 2006 were 17 percent over those of the previous year and this was the 10th straight year for record profit levels. Vasella says record earnings are likely in 2007. Novartis has several new vaccines and new drugs that fight hypertension, diabetes and macular degeneration. The optimistic CEO has laid his hopes on the backs of these drugs. [isokin] Novartis experienced its most impressive results in its Sandoz generic drugs unit. There, sales increased 27 percent to around $6 Billion. Annual turnover rose 15 percent in 2006 to a level of $37. 0 billion. Novartis said it would offer shareholders a 17 percent larger dividend than last year. Financial pundit Jim Cramer plugged the stock in his November 30, 2006 article on thestreet. com website. The Motley Fool website also proclaimed Novartis one of their "Kings of Cash" in a recent article Competitors: Competitors for NVS include: Johnson & Johnson (), Merck & Co. Inc. (), Pfizer Inc. (), Alcon Inc. (), AtheroGenics Inc. (), Alnylam Pharma. Inc. (), Amgen Inc. (), Avanir Pharmas. (), Axcan Pharma Inc. (), AstraZeneca plc (), Bristol-Myers Squibb Co. (), Cephalon Inc. (), GlaxoSmithKline PLC (), Shire PLC (), Taro Pharma. Indus. Ltd. (TARO), Theravance Inc. (), Valeant Pharmas. Intl. (), and Wyeth (). Potential Trades: Although the earnings isokin came in under analyst's predictions, something that might cause a dip in the price today, we are bullish on the stock for the coming month. So let's take a look at February for Novartis using the powerful lens provided to us by the web-based option search tools. For this search, we will use the Strategy Search Summary Tool making sure we check the box for both covered call and bull-call debit spread.
|Covered Call â€“ Novartis AG () $ 59. 53 (30)|
|OPTION||Strike Info||Opt Bid||%Dnsd. Prot.||%If Inch.||%If Asgnd|
|NVSBL||07 FEB 60. 00||$1. 05||1. 80%||1. 80%||2. 60%|
|Bull-Call Debit Spread -- Novartis AG () $ 59. 53 (30)|
|Sell Opt||Strike Info||Bid Price||Buy Option||Strike Info||Ask Price||% Return||Break Even|
|NVSBL||07 FEB $60||$1. 05||NVSBK||07 FEB $55||$5. 00||26. 60%||$58. 95|